Modern adds and follows in Canada. The American biotechnology company has received approval for its vaccine against Covid-19, Spikevax, in the North American country for children between six months and five yearsas reported by the company in a statement.
The primary series of two doses of Spikevax for children in this age group is completed in one month, the same primary dosing schedule as adults, adolescents, and children over five years of age.
Patricia Gauthier, president and general manager of Moderna in Canada, explained that “this decision by Health Canada confirms the efficacy and safety of the company’s vaccine in this last age group.”
Two months ago, the company agreed with the Canadian government to begin production of mRNA vaccines, through the establishment of a vaccine manufacturing plant in the province of Quebec. The agreement is valid for ten years.
Moderna also agreed to build a vaccine factory in Canada
Once operational, the facility is expected to provide access to a portfolio of Canadian-made mRNA vaccines against various respiratory viruses, including Covid-19, seasonal flu, respiratory syncytial virus (RSV), and other potential respiratory viruses.
In the event of a future pandemic, it is expected that the facility can be activated on an urgent basis to support Canada in direct access to rapid response capabilities, with the ability to adapt and adjust manufacturing. The intent is to address emerging new or existing viruses.
In Spain, Moderna plans to end the year manufacturing 500 million doses of its anti-Covid-19 vaccine. So far, the company has manufactured more than 350 million doses of its coronavirus vaccine in the country, which it has already distributed to more than sixty countries.
The biotechnology company also plans to invest 500 million euros in Spain this year. As a result of this investment, the company also plans to build a quality testing laboratory for mRNA vaccines in the Community of Madrid, which is expected to be operational by 2023.
–
